secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0000950170-24-003761
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences licenses azer-cel to TG Therapeutics for $17.5M upfront, up to $288M milestones
--------------------------------------------------------------------------------

- Precision grants TG Therapeutics exclusive license for non-oncology applications of azer-cel, receiving $17.5M in upfront and near-term payments.
- TG Therapeutics to purchase 2,920,816 shares of Precision common stock at $0.77 per share, a 100% premium to 30-day VWAP.
- Precision expects $116M cash as of Dec 31, 2023; combined with deal payments extends cash runway into first half 2026.
- Potential milestone payments up to $288.6M and tiered royalties from mid-single to low-double digit on net sales.
- License covers autoimmune diseases and other non-oncology indications; Precision retains oncology rights with Imugene.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024003761/0000950170-24-003761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024003761/dtil-20240107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer